Sahajanand Medical Technologies Q2 FY27 Revenue Grows 25% to ₹3,734 Million
Sahajanand Medical Technologies reported Q2 FY27 revenue of ₹3,734 million, up 25% YoY. H1 FY27 revenue grew 25% to ₹7,251 million. EBITDA for H1 FY27 increased 43% to ₹1,141 million with margins expanding to 15.7%. The company saw strong growth in the RoW region and across product categories.
The announcement details strong financial performance for the quarter and half-year, including record revenues and profits, which are material to investors and significantly impact the company's valuation and market perception.
The company reported record quarterly performance with significant year-on-year growth in revenue, EBITDA, and PAT, along with expanded margins and improved operational efficiency. Positive commentary from the MD & CEO further reinforces a positive outlook.
Sahajanand Medical Technologies Limited (SMT) announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a record quarter with the highest-ever quarterly revenue, EBITDA, and PAT. For Q2 FY27, revenue grew by 24.7% year-on-year to ₹3,734 million, while EBITDA increased by 36.6% to ₹656 million, with an EBITDA margin of 17.6%. Profit after tax (PAT) rose by 26.6% to ₹265 million.
For the first half of FY27 (H1 FY27), revenue grew by 24.9% to ₹7,251 million, and EBITDA saw a significant increase of 43.4% to ₹1,141 million, with an expanded EBITDA margin of 15.7%. PAT for H1 FY27 was ₹416 million, a 7.5% increase year-on-year (or 38.8% excluding a one-off tax credit in H1 FY26).
The company highlighted growth across all product categories, with 'Other' products growing fastest at 62% in Q2 and IVUSSH accelerating by 40% in Q2. Vascular Interventional (VI) remains the core, contributing 58% of H1 revenue and growing by 16% year-on-year.
Geographically, the Rest of the World (RoW) region emerged as the largest, with H1 FY27 revenue up by 37.1%, driven by strong growth in Q1 (+43.8%) and Q2 (+32.4%). Europe showed steady growth of 23.4% in both quarters, while India's performance picked up with a 14.8% increase in Q2 after a 6.2% rise in Q1.
Operational efficiency remains a key focus, with the cash conversion cycle improving by 16 days to 128 days. The company also emphasized its strengthened product portfolio, including the commercialization of Sironity (sirolimus drug-coated balloon) in India and advancements in its TAVI platform with Hydra Elevate and the redesigned AVDC 1.5 delivery system. The company's R&D expenditure remained robust at approximately 9-10% of revenue.
What to do with a filing like this
Sahajanand Medical Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sahajanand Medical Technologies Limited. Read the original for the full detail.